Published in Immunol Cell Biol on December 18, 2012
B cells and antibodies in the defense against Mycobacterium tuberculosis infection. Immunol Rev (2015) 0.97
The Role of FcRn in Antigen Presentation. Front Immunol (2014) 0.93
Tularemia vaccine development: paralysis or progress? Vaccine (Auckl) (2016) 0.81
Fc receptor-targeting of immunogen as a strategy for enhanced antigen loading, vaccination, and protection using intranasally administered antigen-pulsed dendritic cells. Vaccine (2014) 0.80
In vivo mechanisms involved in enhanced protection utilizing an Fc receptor-targeted mucosal vaccine platform in a bacterial vaccine and challenge model. Infect Immun (2014) 0.78
FcγR mediates TLR2- and Syk-dependent NLRP3 inflammasome activation by inactivated Francisella tularensis LVS immune complexes. J Leukoc Biol (2016) 0.78
Differential Cultivation of Francisella tularensis Induces Changes in the Immune Response to and Protective Efficacy of Whole Cell-Based Inactivated Vaccines. Front Immunol (2017) 0.75
Human neonatal Fc receptor mediates transport of IgG into luminal secretions for delivery of antigens to mucosal dendritic cells. Immunity (2004) 2.79
Francisella tularensis: taxonomy, genetics, and Immunopathogenesis of a potential agent of biowarfare. Annu Rev Microbiol (2006) 2.68
Fc-receptors as regulators of immunity. Adv Immunol (2007) 2.38
Receptor-mediated immunoglobulin G transport across mucosal barriers in adult life: functional expression of FcRn in the mammalian lung. J Exp Med (2002) 2.32
Activating and inhibitory IgG Fc receptors on human DCs mediate opposing functions. J Clin Invest (2005) 2.10
Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A (2004) 1.69
Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol (2000) 1.59
Efficient mucosal vaccination mediated by the neonatal Fc receptor. Nat Biotechnol (2011) 1.47
Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol (2008) 1.36
Enhanced antigen presentation using human Fc gamma receptor (monocyte/macrophage)-specific immunogens. J Immunol (1992) 1.31
Fc receptors for IgG and antigen presentation on MHC class I and class II molecules. Semin Immunol (1999) 1.27
Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice. J Clin Invest (1996) 1.23
Functional characteristics of the high affinity IgG receptor, FcγRI. J Immunol (2011) 1.15
A neonatal Fc receptor-targeted mucosal vaccine strategy effectively induces HIV-1 antigen-specific immunity to genital infection. J Virol (2011) 1.06
Prolonged antigen persistence within nonterminal late endocytic compartments of antigen-specific B lymphocytes. J Immunol (2001) 1.06
Increased potency of Fc-receptor-targeted antigens. Cancer Immunol Immunother (1998) 1.03
The neonatal FcR-mediated presentation of immune-complexed antigen is associated with endosomal and phagosomal pH and antigen stability in macrophages and dendritic cells. J Immunol (2011) 0.99
Immune complexes inhibit differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol (2007) 0.99
Regulation of B-cell activation and antigen presentation by Fc receptors. Curr Opin Immunol (1993) 0.98
Modulation of dendritic cell maturation and function by B lymphocytes. J Immunol (2005) 0.98
Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Arch Immunol Ther Exp (Warsz) (2009) 0.93
Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunol Invest (2005) 0.88
Receptor modulation by Fc gamma RI-specific fusion proteins is dependent on receptor number and modified by IgG. J Immunol (2001) 0.87
Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells. Infect Immun (2011) 0.87
Improving M cell mediated transport across mucosal barriers: do certain bacteria hold the keys? Immunology (2004) 0.85
Differences in IgG subclass do not effect immune complex-enhanced T cell activation despite differential binding to antigen presenting cells. Hum Immunol (1999) 0.82
Cytokine-regulated expression and inhibitory function of FcgammaRIIB1 and -B2 receptors in human dendritic cells. J Leukoc Biol (2005) 0.82
A mucosal gateway for vaccines. Nat Biotechnol (2011) 0.79
Molecular biologic assessment of cutaneous specimens of ocular rosacea. Ophthal Plast Reconstr Surg (2012) 1.96
RpoS is not central to the general stress response in Borrelia burgdorferi but does control expression of one or more essential virulence determinants. Infect Immun (2004) 1.94
Francisella tularensis-infected macrophages release prostaglandin E2 that blocks T cell proliferation and promotes a Th2-like response. J Immunol (2007) 1.39
Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol (2008) 1.36
An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain. Vaccine (2008) 1.35
The crystal structure of Zn(II)-free Treponema pallidum TroA, a periplasmic metal-binding protein, reveals a closed conformation. J Bacteriol (2002) 1.21
The immune response to infection with Treponema pallidum, the stealth pathogen. Microbes Infect (2002) 1.16
Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother (2013) 1.14
Essential role for humoral immunity during Ehrlichia infection in immunocompetent mice. Infect Immun (2005) 1.12
Francisella tularensis LVS grown in macrophages has reduced ability to stimulate the secretion of inflammatory cytokines by macrophages in vitro. Microb Pathog (2006) 1.07
Lipid raft-independent B cell receptor-mediated antigen internalization and intracellular trafficking. J Immunol (2003) 1.06
Francisella tularensis induces ubiquitin-dependent major histocompatibility complex class II degradation in activated macrophages. Infect Immun (2009) 1.04
Host-adaptation of Francisella tularensis alters the bacterium's surface-carbohydrates to hinder effectors of innate and adaptive immunity. PLoS One (2011) 1.02
Broad specificity AhpC-like peroxiredoxin and its thioredoxin reductant in the sparse antioxidant defense system of Treponema pallidum. Proc Natl Acad Sci U S A (2010) 0.99
Development of tolerogenic dendritic cells and regulatory T cells favors exponential bacterial growth and survival during early respiratory tularemia. J Leukoc Biol (2011) 0.98
Differential requirements for protection against mucosal challenge with Francisella tularensis in the presence versus absence of cholera toxin B and inactivated F. tularensis. J Immunol (2009) 0.97
Discordant results obtained with Francisella tularensis during in vitro and in vivo immunological studies are attributable to compromised bacterial structural integrity. PLoS One (2013) 0.97
Functional and structural requirements for the internalization of distinct BCR-ligand complexes. Eur J Immunol (2006) 0.94
Fc receptor-targeted mucosal vaccination as a novel strategy for the generation of enhanced immunity against mucosal and non-mucosal pathogens. Arch Immunol Ther Exp (Warsz) (2009) 0.93
BCR ubiquitination controls BCR-mediated antigen processing and presentation. Blood (2006) 0.93
Identification of Francisella tularensis outer membrane protein A (FopA) as a protective antigen for tularemia. Vaccine (2011) 0.90
The Ia.2 epitope defines a subset of lipid raft-resident MHC class II molecules crucial to effective antigen presentation. J Immunol (2011) 0.89
The pathway of antigen uptake and processing dictates MHC class II-mediated B cell survival and activation. J Immunol (2005) 0.89
Physiological-range temperature changes modulate cognate antigen processing and presentation mediated by lipid raft-restricted ubiquitinated B cell receptor molecules. J Immunol (2010) 0.88
Enhanced antigen-specific antibody and cytokine responses when targeting antigen to human FcGAMMA receptor type I using an anti-human FcGAMMA receptor type I-streptavidin fusion protein in an adjuvant-free system. Immunol Invest (2005) 0.88
Palmitic Acid Is a Novel CD4 Fusion Inhibitor That Blocks HIV Entry and Infection. AIDS Res Hum Retroviruses (2009) 0.87
Dynamics of MHC class II-activating signals in murine resting B cells. J Immunol (2006) 0.87
Three treatments for bilingual children with primary language impairment: examining cross-linguistic and cross-domain effects. J Speech Lang Hear Res (2014) 0.87
Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters. J Biol Chem (2013) 0.87
Francisella tularensis elicits IL-10 via a PGE₂-inducible factor, to drive macrophage MARCH1 expression and class II down-regulation. PLoS One (2012) 0.86
The effect of B cell receptor signaling on antigen endocytosis and processing. Immunol Invest (2004) 0.86
The coenzyme A disulphide reductase of Borrelia burgdorferi is important for rapid growth throughout the enzootic cycle and essential for infection of the mammalian host. Mol Microbiol (2011) 0.86
The Syk-binding ubiquitin ligase c-Cbl mediates signaling-dependent B cell receptor ubiquitination and B cell receptor-mediated antigen processing and presentation. J Biol Chem (2012) 0.85
A two-component modular approach for enhancing T-cell activation utilizing a unique anti-FcgammaRI-streptavidin construct and microspheres coated with biotinylated-antigen. Biomol Eng (2003) 0.85
Immunity to the ehrlichiae: new tools and recent developments. Curr Opin Infect Dis (2005) 0.85
Differential transmembrane domain GXXXG motif pairing impacts major histocompatibility complex (MHC) class II structure. J Biol Chem (2014) 0.84
Price elasticities for three types of CAM services: Experiences of a Boston Public Health Clinic. J Altern Complement Med (2006) 0.84
Evidence that accumulation of mutants in a biofilm reflects natural selection rather than stress-induced adaptive mutation. Appl Environ Microbiol (2006) 0.82
Regulation of CD23 isoforms on B-chronic lymphocytic leukemia. Leuk Res (2002) 0.80
Reactivation of human polyomaviruses in immunocompromised states. J Neurovirol (2014) 0.80
Cis and trans regulatory mechanisms control AP2-mediated B cell receptor endocytosis via select tyrosine-based motifs. PLoS One (2013) 0.79
Providers of complementary and alternative health services in Boston respond to September 11. Am J Public Health (2002) 0.79
Susceptibility and resistance to monocytic ehrlichiosis in the mouse. Ann N Y Acad Sci (2005) 0.78
Analysis of the molecular biologic milieu of the vitreous in proliferative vitreoretinopathy. Retina (2013) 0.78
FcγR-driven release of IL-6 by macrophages requires NOX2-dependent production of reactive oxygen species. J Biol Chem (2013) 0.78
Characterization of the molecular biologic milieu of idiopathic orbital inflammation. Ophthal Plast Reconstr Surg (2011) 0.77
Synthesis, characterization, and biological activity of poly(arginine)-derived cancer-targeting peptides in HepG2 liver cancer cells. J Pept Sci (2014) 0.77
Production of genetically engineered biotinylated interleukin-2 and its application in a rapid nonradioactive assay for T-cell activation. Clin Diagn Lab Immunol (2003) 0.76
Reply re: "molecular biologic assessment of cutaneous specimens of ocular rosacea". Ophthal Plast Reconstr Surg (2013) 0.75
A novel elastin gene mutation in a Vietnamese patient with cutis laxa. Pediatr Dermatol (2014) 0.75
Generation of a human IgG3-streptavidin fusion protein. Implications for the inhibition and elimination of auto-reactive B cells. Hum Antibodies (2003) 0.75
Toll-like receptors in idiopathic orbital inflammation. Ophthal Plast Reconstr Surg (2012) 0.75
Low-level signaling generated by FcgammaRIIB-B cell receptor co-ligation establishes a state of global B cell receptor nonresponsiveness. Immunol Invest (2005) 0.75